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region) in each country. Overall rates of OT/PT visits were reported. Patients who 
reported an OT/PT visit in the past six months were compared with those who did 
not with respect to demographics, health history, and comorbidity variables. Logistic 
regression models were then conducted to predict OT/PT visits from these varia-
bles. Results: Rates of OT/PT visits did not change from 2010 to 2013 but significant 
differences among countries was observed (p< .05). In 2013, France (0.54%) and the 
US (4.51%) had the most infrequent visits while Spain (11.13%) and Germany (11.92%) 
had the most frequent. Being in Germany (OR= 3.46), being in Spain (OR= 3.24), and 
having an above the median income (OR= 1.14) were the strongest demographic 
predictors of an OT/PT visit (all p< .05). Although most comorbidities were associated 
with an increased probability of an OT/PT visit, pain (OR= 2.30), arthritis conditions 
(OR= 1.73), and psychiatric conditions (OR= 1.73) were most strongly associated (all 
p< .05). ConClusions: PT and OT utilization varies significantly across countries, 
being highest in Germany and Spain where over 10% of adults reported a visit in the 
past six months. Pain-related (pain, arthritis) and psychiatric comorbidities were 
among the strongest predictors of PT/OT use.
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objeCtives: Gender is a social construct, which is defined by the way people 
perceive themselves and how they expect others to behave. Gender medicine 
is the field of medicine that studies the biological and physiological differ-
ences between the human sexes and how that affects differences in disease. 
The progress of research has confirmed that men and women differ not only 
sexually but also in relationship to factors such as liver enzymes, sex hor-
mones and to variables determined by the environment, education, culture 
and psychology of the individual [Soldin and Mattison, 2009; Regitz-Zagrosek 
and Seeland 2012]. The Italian Drug Agency has recognized the importance of 
gender-specific analysis when evaluating new drug efficacy. The gender-medi-
cine METAGEM project aims to describe gender differences in clinical outcomes, 
therapeutic approach and safety parameters in real world data. Methods: 
Areas of interest were defined regarding Dermatology, Central nervous system, 
Infectivology, Rheumatology, and Transplantation; data were considered which 
were collected in ten observational studies conducted between 2002 and 2013 
in Italy in routine clinical practice. A post-hoc subgroup analysis is performed 
by study, during which males are compared with females by statistical tests. 
A merge of different study data will be performed in order to evaluate safety. 
As post-hoc analysis all p-values are exploratory. Results: The number of 
enrolled patients range between 238 to 1746 considering Rheumatology 
and Dermatology areas respectively, for a total of 3743 male and 3018 female 
patients. ConClusions: The papers and congress communications which will 
arise from METAGEM project will make the scientific community more aware of 
the importance of a gender-dedicated approach in the care of patients.
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objeCtives: Health economic analysis (HEA) has been required since 2008 as a 
part of drug reimbursement applications submitted to the State Institute for Drug 
Control (SUKL). In 2013, SUKL introduced a formal health economic guideline, mostly 
based on the Czech Pharmacoenomic Society´s guideline published in 2011. The 
aim of this study was to assess the impact of guideline implementation on the 
quality of submitted HEAs. Methods: We reviewed all (18) applications for new 
innovative drugs with prescription limited to specialized centers, in which the 
final decision was issued and came into force between 1/2013-6/2014. The HEAs 
were described in terms of type of analysis and further confronted with a ‘HEA 
checklist‘ to identify common deficiencies in submitted HEAs. All check-lists were 
peer-reviewed to ensure objectivity. Our results were compared with previously 
published research (assessing HEAs submitted in 2008-2009 before the guideline 
release). Results: All investigated dossiers contained HEA. Nine of them (50%) 
were cost-effectiveness analysis (outcome expressed mostly in LYGs) and nine (50%) 
were cost-utility analyses (outcome in QALYs). In general, the quality of HEAs was 
higher compared to the previous research, with ‘evidence completeness’ and ‘uncer-
tainty’ being the most commonly marked as ‘unsatisfactory’ in the HEA checklist 
(less than 50%). Our results showed that 1/3 HEAs fell into the ‘best’ category (80-
100% ‘satisfactory’ questions), while none of HEAs fell into this category in previous 
research. ConClusions: The present analysis showed a trend in higher quality of 
submitted analyses (1/2013-6/2014) compared with years 2008-2009.
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objeCtives: Due to rising health care costs, stricter governmental cost contain-
ment measures like international price comparison and external reference pricing, 
the European pharmaceutical markets will lead to future challenges in pricing. 
Despite of these prices of pharmaceuticals vary across European countries. Thus, 
the aim of the analysis was to draw a comprehensive picture of the pharmaceuti-
cal price levels and consumption (expenditure per capita) of pharmaceuticals in 
Europe. Methods: The study analyzed drug prices of the outpatient setting (Rx 
and OTC) of all countries of the European Union except Denmark plus Switzerland. 
Hungarian Forint / DRG costweight). ConClusions: Introduction of degressive 
financing method – in addition to DRG reimbursement – managed to control the 
activity of hospitals. The soft regulation in 2011 and 2012 resulted in a 4.2-4.6% 
excess activity of hospitals, while the more rigorous regulation in 2013 managed to 
decrease the excess hospital activity to 1.9%. Degressive regulation can serve as a 
cost containment tool for health policy decision makers.
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objeCtives: In the German hospital landscape NuB’s (Neue Untersuchungs- und 
Behandlungsmethoden) are essentially the precursor for cost-intensive drugs to 
be reimbursed within the G-DRG system. Hospitals can only start SHI negotiations 
for reimbursement once drugs have been given a NuB 1 status. The objective of 
this research was to provide an overview on the proportion of drugs (vs. methods, 
medicinal products) and their respective indications, which submitted NuB applica-
tions for 2014. Methods: The German DRG database issued by the InEK (Institute 
for the Hospital Remuneration System) was used to analyse NuB subgroups sorted 
according to key therapeutic indications. In parallel, the number of NuB 1 status 
products that went through the AMNOG process was analysed. Results: Out of 
618 NuB submissions, only 133 (22%) were classified as drugs. In total, 114 (18%) 
of all NuB applications received a NuB 1 status, out of these 43 (38%) were drugs. 
The leading therapeutic area of the NuB 1 status drugs was oncology with 28 drugs 
(65%), followed by 5 ophthalmic products (12%). NuB 2 status was given to 465 (75%) 
procedures out of which 82 (18%) were drugs. The analysis reveals that, the suc-
cess rate to receive the essential NuB 1 status is relatively low. Chances to receive 
a successfull NuB 1 status approval is one in three for drugs, however only one in 
six for other procedures. Out of the 43 drugs that were given NuB 1 status, already 
24 (55%) passed through the AMNOG process and were given equal proportions 
from important additional benefit to no additional benefit. ConClusions: Drug 
applications are more likely than procedures to be given NuB 1 status and thereby 
initiate reimbursement negotiations with the SHI. The application quality and sup-
port by the scientific societies and treatment centres is essential to make a NuB 
application successful.
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objeCtives: The purpose this literature review is to investigate the application of 
multicriteria decision analysis and cost analysis methods within health care deci-
sion-making. Methods: A search of the literature was conducted using scintific 
databases. A combination of the following key words and phrases were inputted 
into these databases: Analytic Hierarchy Process (AHP), Analytic Network Process 
(ANP), ELimination and Choice Expressing REality (ELECTRE), Goal programming, Grey 
relation analysis, Markov process, Technique for Order of Preference by Similarity 
to Ideal Solution (TOPSIS), CBA, CEA, and related words. The located articles were 
divided into the following twelve health care topics: evaluation of health informa-
tion services; evaluation of the product development process; project and technology 
selection; pharmaceutics; health care management; therapy/treatment; management 
of medical waste; human resource planning in health care; organ transplantation; 
evaluation of health care policy; diagnostics; and shared decision-making with the 
patient. Results: Ninety research articles were retrieved and determined relevant. 
The pertinent articles were published between 1981 and 2013. It was found that the 
AHP is the most commonly used method in health care decision making (65 articles). 
AHP is mainly exploited in project and technology selection (22). The ANP method 
is utilized in the evaluation of health information services, project and technology 
selection, pharmaceutics and therapy/treatment. For the evaluation of health care 
policy AHP (11), CBA (1), CEA (1) and Grey relation analysis (1) were used. The TOPSIS, 
VIKOR, Markov process methods were utilized once in human resource planning 
in health care, health care management and therapy/treatment respectively. The 
CBA (4) and CEA (2) methods were especially useful for solving therapy/treatment 
tasks. ConClusions: Multicriteria decision analysis and cost analysis offers a scien-
tifically sound evaluation framework for health care management, where stakeholder 
interests are of crucial concern and complex criteria that cannot easily be reduced to 
simple monetary expressions, can be assessed in resource limited settings.
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objeCtives: Allied health care (AHC) disciplines, such as physical (PT) and occupa-
tional therapy (OT), are primarily performed by non-medical health care profession-
als. Although the budget impact of AHC is generally low, reimbursements are often 
scrutinized for their financial impact and benefit/risk ratios. To better inform the 
health care decision making regarding AHC, the aim of this study was to examine 
trends and utilization of PT and OT. Methods: Data from the 2013 US (N= 75,000) 
and 2013 5EU (France, Germany, Italy, Spain, and UK; N= 62,000) National Health and 
Wellness Survey (NHWS). The NHWS is a patient-reported survey administered to 
a demographically representative sample of adults (with respect to age, sex, and 
